Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMC4 siRNA
- Development stage
- Preclinical
- Lead developer
- Anhui Medical University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
SMC4 siRNA is a small interfering RNA designed to silence the expression of the **Structural Maintenance of Chromosomes 4 (SMC4)** gene via the RNA interference (RNAi) pathway. SMC4 is a critical subunit of the condensin I and II complexes, which are essential for chromosome condensation and segregation during mitosis. In the context of oncology, SMC4 is frequently overexpressed and has been identified as a driver of tumor progression and chemoresistance. Specifically, in hepatocellular carcinoma (HCC), SMC4 promotes resistance to chemotherapy by inducing autophagy. By targeting and facilitating the degradation of SMC4 mRNA, SMC4 siRNA reduces protein levels, thereby inhibiting autophagy-mediated survival mechanisms and sensitizing cancer cells to chemotherapeutic agents. It is currently utilized primarily in preclinical research to explore the therapeutic potential of SMC4 inhibition in various malignancies.
- Other names
- SMC4 small interfering RNASMC-4 small interfering RNASMC 4 small interfering RNAsiRNA targeting SMC4
02
Targets
SMC4
Beyond the preview
Go deeper on SMC4 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMC4 siRNA.